Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Brand Name :
Cantil
Synonyms :
Class :
Anticholinergic Agent and antispasmodics
Dosage Forms & Strengths Â
Tablet- as bromide: Â
25 mg [DSC- discontinued product] Â
Â
Safety and efficacy not established Â
Avoid useÂ
it may increase the effect of anticholinergic agents 
it may increase the effect of anticholinergic agents 
it may increase the constipating effect of eluxadoline 
it may increase the effect of anticholinergic agents 
it may increase the anticholinergic effect of Revefenacin
it increases the effect of anticholinergic agents
they increase the anticholinergic effect of tiotropium
anticholinergic agents increase the efficacy of cimetropium
anticholinergic agents increase the effect of constipation of eluxadoline
it increases the effect of anticholinergic agents
it increases the effect of anticholinergic agents
anticholinergic agents increase the ulcer-producing effect of potassium chloride
it increases the effect of anticholinergic agents
it increases the effect of anticholinergic agents
may increase the risk of adverse effect of other cholinergic antagonistsÂ
may increase the risk of adverse effect of other cholinergic antagonistsÂ
may increase the risk of adverse effect of other cholinergic antagonistsÂ
may increase the risk of adverse effect of other cholinergic antagonistsÂ
may increase the risk of adverse effect of other cholinergic antagonistsÂ
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
May enhance the tachycardic effect
May enhance the tachycardic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
may enhance the adverse/toxic effect
When mepenzolate is used together with profenamine, this leads to enhanced risk or seriousness of adverse events
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may reduce the therapeutic effect of anti-Parkinson drugs
may increase the risk of adverse effect of other cholinergic antagonistsÂ
may increase the risk of adverse effect of other cholinergic antagonistsÂ
may increase the risk of adverse effect of other cholinergic antagonistsÂ
may increase the risk of adverse effect of other cholinergic antagonistsÂ
may increase the risk of adverse effect of other cholinergic antagonistsÂ
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
anticholinergic agents decrease the efficacy of other ACE inhibitors
anticholinergic agents decrease the efficacy of other ACE inhibitors
anticholinergic agents decrease the efficacy of other ACE inhibitors
anticholinergic agents decrease the efficacy of other ACE inhibitors
anticholinergic agents decrease the efficacy of other ACE inhibitors
anticholinergic agents increase the effect of tachycardia of cannabinoid-containing products
anticholinergic agents increase the effect of tachycardia of cannabinoid-containing products
anticholinergic agents increase the toxicity of glucagon
anticholinergic agents decrease the efficacy of itopride
it increases the toxicity of anticholinergic agents
anticholinergic agents diminish the absorption of nitroglycerin
anticholinergic agents increase the toxicity of opioid agents
anticholinergic agents increase the toxicity of opioid agents
anticholinergic agents increase the toxicity of opioid agents
anticholinergic agents increase the toxicity of opioid agents
anticholinergic agents decrease the efficacy of secretin methacholine
Adverse drug reactions:  Â
Frequency not defined Â
Palpitations Â
tachycardia Â
Confusion Â
Dizziness Â
Drowsiness Â
Headache Â
Insomnia Â
nervousness Â
Hypohidrosis Â
urticaria Â
Anaphylaxis Â
Weakness Â
Blurred vision Â
Cycloplegia Â
mydriasis Â
Â
Pregnancy warnings:    Â
Pregnancy Category: BÂ
Breastfeeding warnings: Â
The release of the drug into the human breastmilk is unknownÂ
Pregnancy Categories:     Â
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester.     Â
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women     Â
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women     Â
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits     Â
Category X: Drugs listed in this category outweigh risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.     Â
Category N: There is no data available for the drug under this category
Patient Information Leaflet Â
Generic Name: mepenzolateÂ
Pronunciation: me PEN zoe lateÂ
Why do we use mepenzolate?Â
Mepenzolate is an anticholinergics agent which acts as a antispasmodic drug used to treat peptic ulcerÂ